Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study
暂无分享,去创建一个
A. Salomon | V. Servois | I. Bièche | M. Campone | R. Lidereau | F. Bidard | V. Bernard | S. Giacchetti | P. Cottu | T. Bachelot | E. Brain | W. Chemlali | S. Baulande | M. Saghatchian | L. Belin | B. Zafrani | A. Comte | C. Callens | V. Fourchotte | P. Legoix | K. Driouch | F. Berger | Zakia Tariq | Anais Boulai
[1] B. Kiely,et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) , 2020, Annals of Oncology.
[2] S. Mathoulin-Pélissier,et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016. , 2020, European journal of cancer.
[3] C. Leslie,et al. ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer , 2020, Nature Genetics.
[4] C. Curtis,et al. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases , 2019, Nature Genetics.
[5] G. Mills,et al. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion. , 2019, European journal of cancer.
[6] E. Winer,et al. Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[7] R. Xu,et al. Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. , 2019, JAMA oncology.
[8] F. Bertucci,et al. Genomic characterization of metastatic breast cancers , 2019, Nature.
[9] B. Taylor,et al. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. , 2018, Cancer cell.
[10] S. Vacher,et al. Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer , 2018, Breast Cancer Research.
[11] P. V. van Diest,et al. Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases. , 2018, Cancer research.
[12] P. V. van Diest,et al. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis , 2018, Journal of the National Cancer Institute.
[13] J. Pérez-García,et al. The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies. , 2017, Cancer treatment reviews.
[14] Brent S. Pedersen,et al. Combating subclonal evolution of resistant cancer phenotypes , 2017, Nature Communications.
[15] Robert J. Lonigro,et al. Integrative Clinical Genomics of Metastatic Cancer , 2017, Nature.
[16] Marie-Cécile Le Deley,et al. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. , 2017, Cancer discovery.
[17] Moriah H Nissan,et al. OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.
[18] C. Perou,et al. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. , 2017, Cancer research.
[19] A. Viale,et al. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases , 2017, Clinical Cancer Research.
[20] C. Lefebvre,et al. Mutational Profile of Metastatic Breast Cancers: A Retrospective Analysis , 2016, PLoS medicine.
[21] M. Cheang,et al. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib. , 2016, JAMA oncology.
[22] Lesley Fallowfield,et al. Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] B. Taylor,et al. deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution , 2016, Genome Biology.
[24] Roman Rouzier,et al. Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials , 2015, Journal of the National Cancer Institute.
[25] Adrian V. Lee,et al. Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients , 2015, Clinical Cancer Research.
[26] Nicolas Servant,et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.
[27] R. Schiff,et al. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer , 2015, Nature Reviews Clinical Oncology.
[28] R. Bast,et al. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Andrew Menzies,et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing , 2015, Nature Medicine.
[30] M. Fernö,et al. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] T. Fehm,et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. , 2014, The Lancet. Oncology.
[32] A. González-Angulo,et al. Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study , 2014, Breast Cancer Research and Treatment.
[33] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[34] M. Fernö,et al. St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases - aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial , 2013, BMC Cancer.
[35] David Chen,et al. ESR1 ligand binding domain mutations in hormone-resistant breast cancer , 2013, Nature Genetics.
[36] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[37] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[38] O. Nanni,et al. Hormonal Receptor, Human Epidermal Growth Factor Receptor-2, and Ki67 Discordance between Primary Breast Cancer and Paired Metastases: Clinical Impact , 2012, Oncology.
[39] A. Thompson,et al. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies. , 2012, Cancer treatment reviews.
[40] J. Mefford,et al. Stromal Genes Add Prognostic Information to Proliferation and Histoclinical Markers: A Basis for the Next Generation of Breast Cancer Gene Signatures , 2012, PloS one.
[41] J. Bergh,et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[43] A. Luini,et al. Breast cancer subtypes and outcome after local and regional relapse. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[44] T. Osako,et al. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis , 2011, World journal of surgical oncology.
[45] M. Clemons,et al. Acquisition of metastatic tissue from patients with bone metastases from breast cancer , 2011, Breast Cancer Research and Treatment.
[46] A. Thompson,et al. Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS) , 2010, Breast Cancer Research.
[47] G. Dranitsaris,et al. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases? , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[48] S. Sleijfer,et al. ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients. , 2017, Cancer treatment reviews.
[49] M. Somerfield,et al. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2015, Journal of oncology practice / American Society of Clinical Oncology.
[50] M. Fernö,et al. Gallen molecular subtypes in primary breast cancer and matched lymph node metastases-aspects on distribution and prognosis for patients with luminal A tumours : results from a prospective randomised trial , 2013 .
[51] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[52] T. Economopoulos,et al. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy. , 2006, Anticancer research.
[53] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[54] M. F. Parry,et al. A Retrospective Analysis , 1990 .